| 产品名 | |||
| MI-773 (SAR405838) | Mdm2 | 实体瘤 | Phase 1 |
| Apitolisib (GDC-0980, RG7422) | mTOR | 乳腺癌,前列腺癌,淋巴瘤 | Phase 2 |
| Voxtalisib (SAR245409, XL765) | PI3K | 恶性肿瘤 | Phase 2 |
| Gedatolisib (PF-05212384, PKI-587) | mTOR | 白血病 | Phase 2 |
| PF-04691502 | Akt | 乳腺癌 | Phase 2 |
| Copanlisib (BAY 80-6946) | PI3K | 淋巴瘤 | Phase 3 |
| Vistusertib (AZD2014) | mTOR | 实体瘤 | Phase 2 |
| CC-223 | mTOR | 骨髓瘤,淋巴瘤 | Phase 1/2 |
| Pilaralisib (XL147) | PI3K | 淋巴瘤,乳腺癌 | Phase 2 |
| BGT226 (NVP-BGT226) | mTOR | 实体瘤 | Phase 2 |
| Acalisib (GS-9820) | PI3K | 白血病,淋巴瘤 | Phase 1 |
| GDC-0032 | PI3K | 乳腺癌,肺癌 | Phase 2 |
| GDC-0084 | mTOR | 星形细胞瘤 | Phase 1 |
| SAR-260301 | PI3K | 淋巴瘤 | Phase 1 |
| AMG319 | PI3K | 白血病,头颈癌 | Phase 2 |
| AZD8186 | PI3K | 乳腺癌,肺癌,前列腺癌 | Phase 1 |
| GSK2636771 | PI3K | 实体瘤 | Phase 2 |
| GSK2269557 | PI3K | 阻塞性肺病,哮喘 | Phase 2 |
| Uprosertib (GSK2141795) | Akt | 白血病,乳腺癌,宫颈癌,黑色素瘤,子宫内膜癌 | Phase 2 |
| Afuresertib (GSK2110183) | Akt | 白血病,卵巢癌,骨髓瘤 | Phase 1 |
| MLN1117 (INK1117) | PI3K | 肺癌 | Phase 2 |
| Encorafenib (LGX818) | Raf | 黑色素瘤,结肠直肠癌 | Phase 3 |
| Binimetinib (MEK162, ARRY-438162) | MEK | 输卵管癌,卵巢癌,腹膜癌,黑色素瘤,结肠直肠癌 | Phase 3 |
